US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

6.220 -0.060 (-0.96%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call ↗
Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company... 
Via MarketBeat
Topics Earnings
News headline image
Phathom (PHAT) Q3 2026 Earnings Call Transcript ↗
Revenue surged 71% year-over-year to $84.7 million as VOQUEZNA prescriptions topped 2 million. 
Via The Motley Fool
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Provides Update on FDA Litigation
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals (PHAT) Falls After Cutting 2026 Revenue Guidance Despite Q2 Beat ↗
Via Chartmill
Phathom Pharmaceuticals (NASDAQ:PHAT) Smashes Q1 Expectations, Nears Profitability Milestone ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Management to host conference call on Thursday, October 29, 2026, at 8:00 am EDT 
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings: Revenue Beat and Narrowed Losses Signal Path to Profitability ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Phathom Pharmaceuticals Q2 Earnings Call Highlights ↗
Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first... 
Via MarketBeat
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT 
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q1 2026 Earnings Transcript ↗
Phathom (PHAT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q4 2025 Earnings Call Transcript ↗
Phathom (PHAT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST 
From Phathom Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >